Grace Therapeutics, Inc. (GRCE)
Automate Your Wheel Strategy on GRCE
With Tiblio's Option Bot, you can configure your own wheel strategy including GRCE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GRCE
- Rev/Share 0.0005
- Book/Share 3.9907
- PB 0.7818
- Debt/Equity 0.0
- CurrentRatio 8.8661
- ROIC -0.1769
- MktCap 43145232.0
- FreeCF/Share -0.8232
- PFCF -3.2913
- PE -4.8177
- Debt/Assets 0.0
- DivYield 0
- ROE -0.173
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | GRCE | TD Cowen | -- | Buy | -- | $12 | May 2, 2025 |
News
Grace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104
Published: August 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
FDA Establishes April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Comprehensive Data Package Supported by Positive Results from Phase 3 STRIVE-ON Safety Trial of GTx-104 PRINCETON, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced that on August 22, 2025 the U.S. Food and Drug Administration …
Read More
Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
Held Type C meeting with FDA on Planned New Drug Application (NDA) Submission, Including Clinical, Non-clinical, and Chemistry, Manufacturing, and Control (CMC) Requirements NDA On Track for Submission to FDA in First Half of Calendar 2025 NDA to be Supported by Data from Phase 3 STRIVE-ON Safety Trial, which Met Primary Endpoint and Provided Evidence of Clinical Benefit Compared to Orally Administered Nimodipine Secured Private Placement Financing of $15 Million in Upfront Gross Proceeds with the Potential to Receive up to an Additional $15 Million in Potential Warrant Exercise Proceeds for an Aggregate of Up to Approximately $30 Million in …
Read More
Grace Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
PRINCETON, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) formerly Acasti Pharma Inc. (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that Chief Executive Officer Prashant Kohli will participate in the upcoming TD Cowen 45th Annual Health Care Conference, to be held in Boston, MA, March 3-5, 2025.
Read More
Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
Announced Phase 3 STRIVE-ON Safety Trial Met Primary Endpoint and Provided Clinical Benefit Compared to Orally Administered Nimodipine; New Drug Application (NDA) Submission Anticipated First Half of Calendar 2025 Secured Private Placement Financing of $15 Million in Upfront Gross Proceeds with the Potential to Receive up to an Additional $15 Million in Potential Warrant Exercise Proceeds for an Aggregate of Up to Approximately $30 Million in Potential Total Gross Proceeds PRINCETON, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) formerly Acasti Pharma Inc. (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, …
Read More
About Grace Therapeutics, Inc. (GRCE)
- IPO Date 2012-02-07
- Website https://www.acastipharma.com
- Industry Biotechnology
- CEO Prashant Kohli
- Employees 4